Atopic Dermatitis: New Research on Disease Course and Treatment.
Variable Course of AD
Longitudinal follow-up of 2 large birth cohorts has revealed multiple patterns of AD development. The stereotypical course of early onset-early resolving disease was the most common, but sizable proportions of children who developed the disease followed other patterns (Figure). (1) Although many children outgrow AD by or during adolescence, the disease sometimes persists into later adolescence and adulthood. A 25-study meta-analysis reported that roughly 26% cases of AD began in adulthood ([greater than or equal to]16 years old).
Pediatric and Adult Prevalence
Two recent US-based surveys yielded almost identical prevalence figures of AD in adults--7.2% and 7.3%--for a total of about 16.5 million adults with AD. (3,4) In the United States, the 12-month AD prevalence is 10.7% in children age 17 years and younger. (5) Diagnosing AD in adults is more difficult than diagnosing AD in children. Identifying AD in adults requires not only awareness of the disorder but evaluation of a larger differential diagnosis than in children, including psoriasis, contact dermatitis, and T-cell lymphoma.
How Often Is AD Moderate or Severe?
About one-third of children with AD have moderate or severe disease. (6) Rates of moderate-to-severe disease were higher in adults with AD, at 47%. (4)
Defining Moderate-to-Severe AD in Clinical Practice
A recent consensus report established criteria for defining moderate-to-severe disease in clinical practice (Table 1). (7) Patients with more than 10% of their body surface area affected who have been untreated or undertreated and who respond well to topical therapies may have mild disease.
Many commonly used agents, including antimicrobials, antiseptics, and antihistamines, are not approved by the US Food and Drug Administration (FDA) for AD, and no evidence supports their use. Efficacious older therapies include cyclosporine, corticosteroids, and methotrexate. The newest agents are the topical treatment crisaborole and the systemic biologic dupilumab. The most recent American Academy of Dermatology guidelines predate the newest therapies for AD, (8,9) but the Atopic Dermatitis Yardstick attempts to fill the gap by incorporating current treatments into the algorithm. (10)
Crisaborole, a topical phosphodiesterase-4 inhibitor, was FDA-approved in 2016 for use in AD. Recently it was shown to improve quality of life (QOL) for both patients and their families after 29 days of therapy. The vehicle also improved QOL from baseline, meeting the threshold for a minimal clinically important difference. But improvements with crisaborole significantly exceeded those observed with the vehicle, a petrolatum-based moisturizer. (11)
Dupilumab, an anti-interleukin (IL)-4, anti-IL-13 injectable biologic agent, has received FDA approval to treat AD in adolescents (age [greater than or equal to]12 years) as well as adults. (12) Phase 3 data showing efficacy in an adolescent population with moderate-to-severe AD were presented recently. (13) Interestingly, roughly half of the patients in this trial had asthma at baseline, and dupilumab is FDA-approved as add-on therapy in asthma for adolescents with an eosinophilic phenotype or dependent on oral corticosteroids. (12) This agent may have multiple benefits in this subset of patients.
New Systemic Therapies
At least 5 compounds are in phase 3 development (Table 2) and 15 compounds are in phase 2 development for systemic treatment of AD.
New Topical Therapies
Several new agents are in phase 3 development for use as topical therapies in AD (Table 3). (14-16)
Vitamin D Supplementation
Vitamin D deficiency was correlated with AD severity in children, but vitamin D supplementation did not significantly improve disease severity. (17)
For many patients, AD extends beyond childhood or starts after childhood. Topical crisaborole and the biologic agent dupilumab offer additional treatment options to alleviate the substantial disease burden associated with AD. Additional new topicals and systemic therapies for treating AD are in clinical development.
(1.) Paternoster L, Savenije OEM. Heron J, et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J Allergy Clin Immunol. 201S; 141(3):964-971.
(2.) Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019; 80(6): 1526-1532.e7.
(3.) Hua T, Silverberg J I. Atopic dermatitis in US adults: epidemiology, association with marital status, and atopy. Aim Allergy Asthma Immunol. 2018;121(5):622-624.
(4.) Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018; 121 (3):340-347.
(5.) Shaw TE, Currie GP. Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol 2011;131(1):67-73.
(6.) Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25(3):107-114.
(7.) Boguniewicz M, Alexis AF, Beck LA. et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 20172(6): 1519-1331.
(8.) Sidbury R, Davis DM, Cohen DE. et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014:71(2):327-349.
(9.) Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am A cad Dermatol. 2014;71 (1): 116-132.
(10.) Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e12.
(11.) Simpson EL, Palier AS, Boguniewicz M. et al. Crisaborole ointment improves quality of life of patients with mild to moderate atopic dermatitis and their families. Dermatol Ther (Heidelb). 2018;8(4):605-619.
(12.) Dupixent [prescribing information], Tarrytown, NY: Regeneran Pharmaceuticals; March 2019.
(13.) Simpson EL, Palier AS, Siegfried EC, et al. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study. Presented at: 27th European Academy of Dermatology and Venereology Congress; September 15, 2018; Paris, France. Presentation #4640.
(14.) Peppers J, Palier AS. Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(1):89-98.e83.
(15.) Hanifin JM. Ellis CN, Frieden IJ, et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016;75(2):297-305.
(16.) Lee YW, Won CH. Jung K, et al. Efficacy and safety of PAC-14028 cream-a novel, topical, non-steroidal selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase lib randomized trial. Br J Dermatol. 2019; 180(5): 1030-1038.
(17.) Lara-Corrales I, Huang CM, Parkin PC, et al. Vitamin D level and supplementation in pediatric atopic dermatitis: a randomized controlled trial. J Cutan Med Surg. 2019;23(l):44-49.
TABLE 1. Clinical Criteria for Moderate-to-Severe AD (7) * Involvement of [greater than or equal to]10% BSA * Regardless of degree of BSA involvement: ** Individual lesions with moderate-to-severe features ** Involvement of highly visible areas or areas important for function (eg, neck, face, genitals, palms, and/or soles) ** Significantly impaired QOL Clinicians should actively assess the impact of disease on QOL during clinic visits (ie, sleep, pruritus, activities of daily living, and work). AD, atopic dermatitis; BSA, body surface area; QOL, quality of life. TABLE 2. Targeted Systemic Treatments for AD in Phase 3 Development Drug Treatment Type Target Trial Identifier Tralokinumab Biologic IL-13 NCT03363854 Baricitinib Small molecule JAK1/JAK2 NCT03435081 Abrocitinib Small molecule JAK1 NCT03796676 (PF-04965842) Upadacitinib Small molecule JAK1 NCT03569293 Tradipitant Small molecule NK1 receptor NCT03568331 AD, atopic dermatitis; IL-13, Interleukin 13; JAK, Janus kinase; NK1, neurokininl. Trial identifier; www.clinicaltrials.gou. TABLE 3. Topical Treatments for AD in or Near Phase 3 Development Drug Target Trial Identifier Delgocitinib All JAK NCT03725722 Ruxolitinib JAK1/JAK2 NCT03745638 NCT03745651 Tapinarof (14) Aryl hydrocarbon -- receptor OPA-15406 (15) PDE-4 NCT03911401 IDP-124 Not reported NCT03058783 PAC-14028 (16) TRPV1 NCT02965118 AD, atopic dermatitis; JAK, Janus kinase; PDE4, phosphodiesterase 4; TRPV1, transient receptor potential vanilloid subfamily, member 1. Trial identifier: www.clinicaltrials.gov. FIGURE. Diverse Patterns of Atopic Dermatitis Onset and Resolution Birth Cohort 1: ALSPAC Unaffected/transient 58.0% Early onset--early resolving 12.9% Early onset-persistent 7.3% Early onset-late resolving 7.0% Mid-onset-resolving 7.0% Late onset-resolving 7.9% Birth Cohort 2: PIAMA Unaffected/transient 62.9% Early onset--early resolving 15.4% Early onset-persistent 4.9% Early onset-late resolving 3.8% Mid-onset-resolving 6.5% Late onset-resolving 6.5% ALSPAC, Avon Longitudinal Study of Parents and Children; PIAMA, Prevention and Incidence of Asthma and Mite Allergy. Source; Paternoster L, et al. J Allergy Clin Immunol. 2018;141:964-971. (1) Note: Table made from pie chart.
|Printer friendly Cite/link Email Feedback|
|Author:||Silverberg, Jonathan I.|
|Date:||Aug 1, 2019|
|Previous Article:||Cardiovascular Disease and Psoriasis.|
|Next Article:||Acne: Step Up the Use of Nonantibiotic Systemic Therapy.|